Benzinga | Feb 2, 2021 11:52AM EST

BMO Capital Maintains Outperform on Vertex Pharmaceuticals, Lowers Price Target to $284

BMO Capital analyst Do Kim maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Outperform and lowers the price target from $302 to $284.